Leukemia and Lymphoma

Aflac Cancer & Blood Disorders Center
CHILDREN'S HEALTHCARE OF ATLANTA

ALL treatment protocols			
Study	**Clinical trial name**	**Phase/type**	**Age**
COG AALL1631	AALL1631, International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones https://clinicaltrials.gov/ct2/show/NCT03007147	III	>1 to ≤21 yr
20140106 (formerly ONYX CFZ008)	Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia https://clinicaltrials.gov/ct2/show/NCT02303821	Ib/II	≤18 yr
COG AALL1731 REQ for B-ALL	AALL1731, A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy) https://clinicaltrials.gov/ct2/show/NCT03914625?term=AALL1731&rank=1	III	≥365 days to <10 yr (B-ALL wo/DS) ≥365 days to ≤31 yr (B-ALL w/DS and B-LLy w or wo DS)
COG AALL1732 REQ for B-ALL, MPAL	AALL1732, A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy https://clinicaltrials.gov/ct2/show/NCT03959085	III	>365 days to <25 yr
COG AALL1521 [Incyte]	INCB 18424-269: A Phase 2 Study of JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with *De Novo* High-Risk CRLF2-rearranged and/or JAK Pathway-mutant Acute Lymphoblastic Leukemia https://clinicaltrials.gov/ct2/show/NCT02723994	II	>1 to ≤21 yr
COG AALL1621	AALL1621, A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL) https://clinicaltrials.gov/ct2/show/NCT02981628	II	≥1 to <22 yr
Novartis Cassiopeia (AALL1721)	A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL) who are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy https://clinicaltrials.gov/ct2/show/NCT03876769	II	1 to 25 yr

COG ADVL1823	ADVL1823, Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias https://clinicaltrials.gov/ct2/show/NCT03834961	II	≤30 yr
JNJ Darutumumab	An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects ≥1 and ≤30 Years of Age With Relapsed/ Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma https://clinicaltrials.gov/ct2/show/NCT03384654	II	≥1 to ≤30 yr
COG AALL15P1	AALL15P1, A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement https://clinicaltrials.gov/ct2/show/NCT02828358	Pilot	<1 yr (>36 wk gesta-tional age)
Novartis CART ELIANA	Protocol CCTL019B2202: A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients with Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia https://clinicaltrials.gov/ct2/show/NCT02435849	II	≥3 to ≤21 yr

Novartis CART FU	Protocol No.CCTL019A2205B: Long Term Follow-up of Patients Exposed to Lentiviral-Based CD19 directed CART Cell Therapy https://clinicaltrials.gov/ct2/show/NCT02445222	NA	any age *(received anti-CD19 directed CART therapy)*
TACL 2012-002	A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination with UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults with Relapse of Acute Lymphoblastic Leukemia https://clinicaltrials.gov/ct2/show/NCT02879643	Pilot	≥1 to ≤21 yr
AflacLL1602 ENCERT	ENCERT: A Phase 1 Trial using Everolimus in combination with Nelarabine, Cyclophosphamide and Etoposide in Relapsed T cell Lymphoblastic Leukemia/Lymphoma https://clinicaltrials.gov/ct2/show/NCT03328104	I	>1 to <30 yr
AbbVie M13-833	A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients with Relapsed or Refractory Malignancies https://clinicaltrials.gov/ct2/show/NCT03236857	I	<25 yr
AINV18P1	A Phase 1 Study of Palbociclib (IND# 141416), A CDK 4/6 Inhibitor, in Combination with Chemotherapy in Children with Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) https://clinicaltrials.gov/ct2/show/NCT03792256	I	≥12 mo to ≤31 yr

LEAP	Matched Targeted Therapy (MTT) Recommendation for Patients with Recurrent, Refractory, or High Risk Leukemias https://clinicaltrials.gov/ct2/show/NCT02670525	Feasibility	≤30 yr
ALL biology, supportive treatment and non-therapeutic protocols			
AflacPM1702	Aflac Precision Medicine Program (APMP) Study	Non-therapeutic	<30 yr
COG APEC14B1	APEC14B1: The Project:Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study https://clinicaltrials.gov/ct2/show/NCT02402244	Non-therapeutic	≤25 yr

ACCL1333/ CV185155	A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B cell) Treated with Pegylated (PEG) L-Asparaginase https://clinicaltrials.gov/ct2/show/NCT02369653	III	1 to <18 yr
COG ALTE03N1	Key Adverse Events after Childhood Cancer (cardiac, stroke, secondary malig)/closed to AVN patients as of 11-26-08 https://clinicaltrials.gov/ct2/show/NCT00082745	Non-therapeutic	≤21 yr at dx
COG ALTE05N1	Umbrella Long-Term Follow-Up Protocol https://clinicaltrials.gov/ct2/show/NCT00736749	Non-therapeutic	All ages
COG ALTE07C1	ALTE07C1, Neuropsychological, Social, Emotional and Behavioral Outcomes in Children with Cancer https://clinicaltrials.gov/ct2/show/NCT00772200	Non-therapeutic	3 to <22 yr
COG ALTE1631	ALTE1631, A Randomized Web-based Physical Activity Intervention among Children and Adolescents with Acute Lymphoblastic Leukemia https://clinicaltrials.gov/ct2/show/NCT03223753	NA	≥8 to ≤16 yr
MIPLATE	Clinical Effectiveness of Conventional Versus Mirasol-treated Apheresis Platelets in Patients with Hypoproliferative Thrombocytopenia (MIPLATE) https://clinicaltrials.gov/ct2/show/NCT02964325	Non-therapeutic	>10 kg
AML treatment protocols			
COG AAML1531	Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome https://clinicaltrials.gov/ct2/show/NCT02521493	III	>90 days to <4 yr

COG ADVL1521	ADVL1521: A Phase 2 Study of the MEK Inhibitor Trametinib (IND #119346, NSC# 763093) in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia https://clinicaltrials.gov/ct2/show/NCT03190915	II	≥2 to <22 yr
COG ADVL1823	ADVL1823, Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias https://clinicaltrials.gov/ct2/show/NCT03834961	II	≤30 yr
AC220-A-U202 (ADVL1822)	A Phase 1/2, Multi-center, Dose-escalating Study to Evaluate the Safety, Pharmacokinetics, Pharmaconynamics, and Efficacy of Quizartinib Administered in Combination with Re-induction Chemotherapy, and as a Single-agent Continuation Therapy, in Pediatric Relapsed/Refractory AML Subjects Aged 1 Month to <18 Years (and Young Adults Aged up to 21 Years) with FLT3-ITD Mutations https://clinicaltrials.gov/ct2/show/NCT03793478	I/II	≥1 mo to <21 yr
TACL 2016-002	TACL2016-002: A TACL Phase 1/2 Study of Nivolumab in Combination with 5-azacytidine in pediatric patients with relapsed/refractory acute myeloid leukemia (BMS reference CA209-9JY)	I/II	>1 to ≤30 yr
AflacLL1901	CHOA-AML: A Pilot Study for Newly Diagnosed Pediatric Patients with Acute Myeloid Leukemia (AML)	Pilot	<21 yr
AAML18P1	Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)	Pilot	<18 yr at diag; <25 yr at enroll
TACL 2016-003	Epigenetic Reprogramming in Relapse AML: A Phase 1 Study of Decitabine and Vorinostat Followed by Fludarabine, Cytarabine and G-CSF (FLAG) in Children and Young Adults with Relapsed/Refractory AML https://clinicaltrials.gov/ct2/show/NCT03263936	I	≥1 to ≤25 yr
AbbVie M13-833	A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients with Relapsed or Refractory Malignancies https://clinicaltrials.gov/ct2/show/NCT03236857	I	<25 yr
ADVL1712	ADVL1712, A Feasibility Trial of MLN4924 (Pevonedistat, TAK 924, IND#142772) Given in Combination with Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia or Relapsed Myelodysplastic Syndrome https://clinicaltrials.gov/ct2/show/NCT03813147	I	≥1 mo to ≤21 yr

LEAP	Matched Targeted Therapy (MTT) Recommendation for Patients with Recurrent, Refractory, or High Risk Leukemias https://clinicaltrials.gov/ct2/show/NCT02670525	Feasibility	≤30 yr
AML biology, supportive treatment and non-therapeutic protocols			
AflacPM1702	Aflac Precision Medicine Program (APMP) Study	Non-therapeutic	<30 yr
COG APEC14B1	APEC14B1: The Project:Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study https://clinicaltrials.gov/ct2/show/NCT02402244	Non-therapeutic	≤25 yr
COG ALTE03N1	Key Adverse Events after Childhood Cancer (cardiac, stroke, secondary malig)/closed to AVN patients as of 11-26-08 https://clinicaltrials.gov/ct2/show/NCT00082745	Non-therapeutic	≤21 yr at dx
COG ALTE05N1	Umbrella Long-Term Follow-Up Protocol https://clinicaltrials.gov/ct2/show/NCT00736749	Non-therapeutic	All ages
Arnold PCORI	Home of Away from Home: Comparing Clinical Outcomes Relevant to the Care of Pediatric Acute Myeloid Leukemia during Periods of Neutropenia [Aim 3 closed to accrual; Aim 1 open] https://clinicaltrials.gov/ct2/show/NCT02774850	Non-therapeutic	Any age

NHL treatment protocols			
COG AALL1731 REQ for B-ALL	AALL1731, A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy) https://clinicaltrials.gov/ct2/show/NCT03914625?term=AALL1731&rank=1	III	≥365 days to <10 yr (B-ALL wo/DS) ≥365 days to ≤31 yr (B-ALL w/DS and B-LLy w or wo DS)
COG AALL1732 REQ for B-ALL, MPAL	AALL1732, A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy https://clinicaltrials.gov/ct2/show/NCT03959085	III	>365 days to <25 yr
Novartis BIANCA	Protocol CCTL019C2202: A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Safety and Efficacy of Tisagenlecleucel in Pediatric Patients with Relapsed or Refractory Mature B-cell non-Hodgkin Lymphoma (NHL) (BIANCA) https://clinicaltrials.gov/ct2/show/NCT03610724	II	<18 yr

COG ANHL12P1	A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC#749710), or Crizotinib (NSC#749005, commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND #117117 https://clinicaltrials.gov/ct2/show/NCT01979536	II	<22 yr
COG APEC1621A[REQ]	APEC1621A: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions https://clinicaltrials.gov/ct2/show/NCT03213704	II	≥12 mo to ≤21 yr
COG APEC1621B[REQ]	APEC1621B: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Relapsed Pediatric Solid Tumors Harboring FGFR1/2/3/4 Alterations https://clinicaltrials.gov/ct2/show/NCT03210714	II	≥12 mo to ≤21 yr
COG APEC1621C[REQ]	APEC1621C: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients with Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex https://clinicaltrials.gov/ct2/show/NCT03213665	II	≥12 mo to ≤21 yr
COG APEC1621D[REQ]	APEC1621D NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03213678	II	≥12 mo to ≤21 yr
COG APEC1621E[REQ]	APEC1621E NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Selumetinib in Patients with Tumors Harboring Activating MAPK Pathway Mutations https://clinicaltrials.gov/ct2/show/NCT03213691	II	≥12 mo to ≤21 yr
COG APEC1621F[REQ]	APEC1621F NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations https://clinicaltrials.gov/ct2/show/NCT03213652	II	≥12 mo to ≤21 yr
COG APEC1621G[REQ]	APEC1621G NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Actionable BRAF V600 Mutations https://clinicaltrials.gov/ct2/show/NCT03220035	II	≥12 mo to ≤21 yr
COG APEC1621H[REQ]	APEC1621H NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes https://clinicaltrials.gov/ct2/show/NCT03233204	II	≥12 mo to ≤21 yr

COG APEC1621I[REQ]	APEC1621I NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes https://clinicaltrials.gov/ct2/show/NCT03526250	II	≥12 mo to ≤21 yr
COG APEC1621J[REQ]	APEC1621J NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations https://clinicaltrials.gov/ct2/show/NCT03698994	II	≥12 mo to ≤21 yr
COG ADVL1721	A Non-randomized, Open-label, Multi-center, Phase I/II Study of PI3K Inhibitor Copanlisib in Pediatric Patients with Relapsed/ Refractory Solid Tumors or Lymphoma https://clinicaltrials.gov/ct2/show/NCT03458728	I/II	≥6 mo to ≤21 yr
COG ANHL1522	ANHL1522, A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-specific Cytotoxic T-Lymphocytes (LMP-TC, IND # 17068) in Pediatric Solid Organ Recipients (SOT) with EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD) https://clinicaltrials.gov/ct2/show/NCT02900976	Pilot	<30 yr
COG ADVL1414	ADVL1414, A Phase 1 Study of Selinexor (KPT-330, IND# 125052), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, including CNS Tumors https://clinicaltrials.gov/ct2/show/NCT02323880	I	≥12 mo to ≤21 yr
COG ADVL1615	ADVL1615, A Phase 1 Study of Pevonedistat (MLN4924 IND# 136078), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03323034	I	Part A1: ≥12 mo to ≤21 yr Part A2: ≥6 mo to <12 mo
AbbVie M13-833	A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients with Relapsed or Refractory Malignancies https://clinicaltrials.gov/ct2/show/NCT03236857	I	<25 yr
NHL biology, supportive treatment and non-therapeutic protocols			
AflacPM1702	Aflac Precision Medicine Program (APMP) Study	Non-therapeutic	<30 yr
COG APEC14B1	APEC14B1: The Project:Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study https://clinicaltrials.gov/ct2/show/NCT02402244	Non-therapeutic	≤25 yr
COG APEC1621SC	APEC1621SC: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol https://clinicaltrials.gov/ct2/show/NCT03155620	NA	≥12 mo to ≤21 yr

COG ALTE03N1	Key Adverse Events after Childhood Cancer (cardiac, stroke, secondary malig)/closed to AVN patients as of 11-26-08 https://clinicaltrials.gov/ct2/show/NCT00082745	Non-therapeutic	≤21 yr at dx
COG ALTE05N1	Umbrella Long-Term Follow-Up Protocol https://clinicaltrials.gov/ct2/show/NCT00736749	Non-therapeutic	All ages
Hodgkin disease treatment protocols			
SWOG S186	A Phase III, Randomized Study of Nivolumab (Opdivo) plus AVD or Brentuximab Vedotin (Adcetris) plus AVD in Patients (Age >/= 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma https://clinicaltrials.gov/ct2/show/NCT03907488	III	≥12 yr
COG AHOD1721 CA209744	Risk-based, Response-adapted, Phase II Open-label Trial of Nivolumab + Brentuximab Vedotin (N + Bv) for Children, Adolescents, and Young Adults with Relapsed/refractory (R/R) CD30 + Classic Hodgkin lymphoma (cHL) after Failure of First-line Therapy, Followed by Brentuximab + Bendamustine (Bv + B) for Participants with a Suboptimal Response https://clinicaltrials.gov/ct2/show/NCT02927769	II	5 to 30 yr
COG AHOD1822 (MK3475-667)	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667) https://clinicaltrials.gov/ct2/show/NCT03407144	II	≥3 to ≤25 yr
COG ADVL1721	A Non-randomized, Open-label, Multi-center, Phase I/II Study of PI3K Inhibitor Copanlisib in Pediatric Patients with Relapsed/ Refractory Solid Tumors or Lymphoma https://clinicaltrials.gov/ct2/show/NCT03458728	I/II	≥6 mo to ≤21 yr
COG ADVL1414	ADVL1414, A Phase 1 Study of Selinexor (KPT-330, IND# 125052), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, including CNS Tumors https://clinicaltrials.gov/ct2/show/NCT02323880	I	≥12 mo to ≤21 yr
COG ADVL1615	ADVL1615, A Phase 1 Study of Pevonedistat (MLN4924 IND# 136078), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03323034	I	Part A1: >12 mo to ≤21 yr Part A2: ≥6 mo to <12 mo
Hodgkin disease biology, supportive treatment and non-therapeutic protocols			
AflacPM1702	Aflac Precision Medicine Program (APMP) Study	Non-therapeutic	<30 yr
COG APEC14B1	APEC14B1: The Project:Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study https://clinicaltrials.gov/ct2/show/NCT02402244	Non-therapeutic	≤25 yr

COG ALTE03N1	Key Adverse Events after Childhood Cancer (cardiac, stroke, secondary malig)/closed to AVN patients as of 11-26-08 https://clinicaltrials.gov/ct2/show/NCT00082745	Non-therapeutic	≤21 yr at dx
COG ALTE05N1	Umbrella Long-Term Follow-Up Protocol https://clinicaltrials.gov/ct2/show/NCT00736749	Non-therapeutic	All ages